Chronic News and Research

RSS

Decreased collagen may make women more susceptible to pelvic organ prolapse

Decreased collagen levels might make some women more susceptible to pelvic organ prolapse and urinary incontinence, according to a new study by physicians at Temple University School of Medicine and Temple University Hospital. The study, “Collagen content of nonsupport tissue in pelvic organ prolapse and stress urinary incontinence,” appears in a recent issue of the American Journal of Obstetrics and Gynecology.

22 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

22 Mar 2004

Liverpool scientist presents chronic illness study to House of Commons

A social scientist from the University of Liverpool has visited the House of Commons to present preliminary findings of an innovative research project to MPs.

22 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004

Japanese study raises concerns for childhood health issues

The number of children suffering from mental disorders and health problems such as allergies and asthma has risen sharply over the past decade in this country. The United States and European countries are also facing the increasingly serious problems of premature births and childhood obesity, in addition to allergic reactions. Many experts say the rise in health problems involving children is related to the use of chemicals in our daily lives and the impact of medical treatment provided to the children's mothers.

22 Mar 2004

New optical glucose sensor could mean help for diabetics

Researchers at the University of California, Santa Cruz, have developed a novel optical glucose sensor that could be used to provide continuous monitoring of glucose levels in diabetics and hospitalized patients. Recently published studies showed that the sensor detects glucose under physiological conditions, giving a reversible fluorescent signal that changes intensity in response to changes in the concentration of glucose.

22 Mar 2004

Bacteria Live in the Esophagus!

The esophagus isn't merely a tube for food traveling from the mouth to the stomach, it also provides an environment for bacteria to live, according to a new study by NYU School of Medicine scientists that overturns the general belief that the esophagus is free of bacteria.

22 Mar 2004

Tablet of Modafinil may improve a schizophrenics memory

Researchers from the Department of Psychiatry at the University of Cambridge recently identified a method of improving cognitive functioning in patients with schizophrenia, without the side-effects traditionally found with cognitive enhancers. Ms. Danielle Turner, together with colleagues from the University of Cambridge under the supervision of Prof. Barbara Sahakian, undertook research to explore the potential for a memory drug to improve cognition in patients with schizophrenia. The project received funding from the Wellcome Trust and the Medical Research Council. The work was published online on March 10 2004 at The American College of Neuropsychopharmacology website and is now in press in the journal Neuropsychopharmacology.

22 Mar 2004

Cigarette Smoking May Lower Rates of Neurodegenerative Diseases like Parkinson's and Alzheimer's

While the health risks of tobacco are well known, several studies have shown that people with a history of cigarette smoking have lower rates of neurodegenerative diseases like Parkinson's and Alzheimer's disease. However, the explanations for nicotine's neuroprotective effects continue to be debated.

22 Mar 2004